Shortening Hospital Stay Is Feasible and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
02 2019
Historique:
received: 25 10 2018
revised: 03 12 2018
accepted: 03 12 2018
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 19 11 2019
Statut: ppublish

Résumé

There is no consensus on the length of hospital stay (LOHS) and post-interventional management after balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). We examined temporal trends with respect to LOHS and requirement for intensive care for BPA and their relationship with the incidence of BPA-related complications. From November 2012 to September 2017, a total of 123 consecutive patients with CTEPH who underwent BPA were enrolled (age: 66.0 [54.0 to 74.0], World Health Organization [WHO] functional class II/III/IV; 27/88/8). Patients were divided for analysis into 3 groups according to the date of their first BPA: early-, middle-, and late-phase groups. Mean pulmonary arterial pressure decreased from 36.0 (29.0 to 45.0) to 20.0 (16.0 to 22.0) mm Hg after BPA (P < 0.001). The LOHS was 41.0 (31.0 to 54.0) days in total including all sessions and 6.6 (6.0 to 7.9) days/session. Despite no significant differences in age, baseline hemodynamics, and laboratory data among the 3 groups, there was a significant reduction in LOHS (7.9 [7.0 to 9.5], 6.5 [6.1 to 7.3], 6.0 [5.3 to 6.5] days/session, P < 0.001) and use of intensive/high care unit (100%, 93%, 46%, P < 0.001). The reduction in LOHS and intensive/high care unit use did not affect the occurrence of BPA-related complications. Increasing experience with BPA was associated with a reduction in LOHS and the use of intensive/high care unit, but no change was noted in the rate of BPA-related complications. These findings suggest that the reduction in both LOHS and use of the intensive care unit for BPA is feasible and does not jeopardize the safety of the procedure.

Sections du résumé

BACKGROUND
There is no consensus on the length of hospital stay (LOHS) and post-interventional management after balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). We examined temporal trends with respect to LOHS and requirement for intensive care for BPA and their relationship with the incidence of BPA-related complications.
METHODS
From November 2012 to September 2017, a total of 123 consecutive patients with CTEPH who underwent BPA were enrolled (age: 66.0 [54.0 to 74.0], World Health Organization [WHO] functional class II/III/IV; 27/88/8). Patients were divided for analysis into 3 groups according to the date of their first BPA: early-, middle-, and late-phase groups.
RESULTS
Mean pulmonary arterial pressure decreased from 36.0 (29.0 to 45.0) to 20.0 (16.0 to 22.0) mm Hg after BPA (P < 0.001). The LOHS was 41.0 (31.0 to 54.0) days in total including all sessions and 6.6 (6.0 to 7.9) days/session. Despite no significant differences in age, baseline hemodynamics, and laboratory data among the 3 groups, there was a significant reduction in LOHS (7.9 [7.0 to 9.5], 6.5 [6.1 to 7.3], 6.0 [5.3 to 6.5] days/session, P < 0.001) and use of intensive/high care unit (100%, 93%, 46%, P < 0.001). The reduction in LOHS and intensive/high care unit use did not affect the occurrence of BPA-related complications.
CONCLUSIONS
Increasing experience with BPA was associated with a reduction in LOHS and the use of intensive/high care unit, but no change was noted in the rate of BPA-related complications. These findings suggest that the reduction in both LOHS and use of the intensive care unit for BPA is feasible and does not jeopardize the safety of the procedure.

Identifiants

pubmed: 30760426
pii: S0828-282X(18)31325-4
doi: 10.1016/j.cjca.2018.12.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

193-198

Informations de copyright

Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Mai Kimura (M)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Takashi Kohno (T)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. Electronic address: kohno.a2@keio.jp.

Takashi Kawakami (T)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Masaharu Kataoka (M)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Takahiro Hiraide (T)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Hidenori Moriyama (H)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Sarasa Isobe (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Toshimitsu Tsugu (T)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Yuji Itabashi (Y)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Mitsushige Murata (M)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Shinsuke Yuasa (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Keiichi Fukuda (K)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH